


The importance of w

Despite the multiple publicly available clinical guidelines and research initiatives, many questions remain unanswered regarding pain management and OUD care. Therefore, research on best practices for pain management, including practices for interdisciplinary coordination and strategies to overcome barriers to care is needed to improve the state of pain care during the COVID-19 pandemic and beyond [32]. Once established, support for the implementation and dissemination of evidence-based approaches for multimodal care and appropriate payment models for the provision of this care will be critical. Highlighting and advancing opportunities to strengthen integral aspects of pain management and the translation of pain guidelines into practice can contribute to sustainable improvements across the pain care continuum and ultimately help curb the opioid epidemic.



- Investigate the potential relationship between non-pharmacological pain management interventions and the need for opioids to control pain across diverse patient populations [4]pui

The National Academy of Medicine’s Action Collaborative on Countering the U.S. Opioid Epidemic is a public-private partnership composed of more than 60 organizations representing federal, state, and local governments; health systems; associations and provider groups; health education and accrediting institutions; pharmacies; payers; industry; nonprofits; and academia. The Action Collaborative is committed to developing, curating, and disseminating multi-sector solutions designed to reduce opioid misuse and improve outcomes for individuals, families, and communities affected by the opioid crisis. The Action Collaborative’s work focuses on four key areas: health professional education and training; pain management guidelines and evidence standards; prevention, treatment, and recovery services; and research, data, and metrics needs. Learn more about the Action Collaborative at: [nam.edu/Opioid\\_Collaborative](http://nam.edu/Opioid_Collaborative).

This research agenda, developed on behalf of the Action Collaborative, benefited greatly from the guidance of the Research, Data, and Metrics Needs Working Group, whose members include **Carlos Blanco, MD, PhD**, National Institute on Drug Abuse; **Kelly J. Clark, MD, MBA**, American Society of Addiction Medicine; **Rebecca Baker, PhD**, National Institutes of Health; **David Beier, JD**, Bay City Capital; **Richard Bonnie, LLB**, University of Virginia; **Kathy Chappell, PhD, RN, FNAP, FAAN**, American Nurses Credentialing Center; **Humayun “Hank” J. Chaudhry, DO, MS, MACP**, Federation of State Medical Boards; **Jianguo Cheng, MD, PhD**, American Academy of Pain Medicine; **Kyle P. Edmonds, MD, FAAHPM**, American Academy of Hospice and Palliative Medicine; **James Gifford, MD, FACP**, Federation of State Medical Boards; **Lisa Hines, PharmD**, Pharmacy Quality Alliance; **Christopher M. Jones, PharmD, MPH**, US Centers for Disease Control and Prevention; **Kelly King, PhD, MPH**, American Institutes of Research; **Kevin Larsen, MD, FACP**, Optum Labs; **Bertha K. Madras, PhD**, McLean Hospital and Harvard Medical School; **Edward Mariano, MD, MS**, American Society of Anesthesiologists; **Ray Mitchell, MD, MBA**, Liaison Committee on Medical Education; **Vincent G. Nelson, MD, MBA**, Blue Cross Blue Shield Association; **Robert “Chuck” Rich, Jr., MD, FAAFP**, American Academy of Family Physicians; **Friedhelm Sandbrink, MD**, US Department of Veterans Affairs; and **Steve Singer, PhD**, Accreditation Council for Continuing Medical Education.

Please note this in an excerpt from the full research agenda. The research agenda and complete list of references can be found here: [www.nam.edu/opioid-collaborative-agenda](http://www.nam.edu/opioid-collaborative-agenda)

Disclaimer: The views expressed in this research agenda are those of individual experts and not necessarily of the individuals' or their affiliated organizations.